Skip to main content
NSF Home

TGA Update: New Guidance on Australian UDI Compliance Timeframes

Date
June 3, 2026
Category

Other Regulations

Description

In May 2026, the Therapeutic Goods Administration (TGA) released an updated version (Version 2.0) of its guidance on Unique Device Identification (UDI) compliance timeframes. This document is a critical resource for sponsors and manufacturers to ensure their medical devices remain compliant while being supplied in the Australian market.

Key Updates in Version 2.0: The latest revision includes several important clarifications and new sections designed to streamline the transition to the Australian UDI system (AusUDID). The main updates include:

  • Clarification of "Existing Devices": Enhanced definitions for devices manufactured and labelled prior to their specific compliance start dates.
  • Sponsor Control: Refined definitions of "sponsor control" to help determine when existing Class III and IIb devices must be relabelled.
  • EU Transitional Arrangements: Detailed guidance on how the EU MDD to EU MDR and EU IVDD to EU IVDR transitions align with Australian UDI requirements.
  • Consignment Stock and Surgical Loan Kits (SLKs): New dedicated sections explaining UDI obligations for devices held in consignment or as part of SLKs.

The UDI Procedure in Australia: The Australian UDI system is being implemented in a phased approach over five years to allow the industry to prepare progressively. Compliance involves two primary milestones:

  1. UDI Labelling and Record Submission: Manufacturers must allocate UDI-DIs and UDI-PIs and apply compliant labelling to the device and packaging. Sponsors are then responsible for submitting these records to the AusUDID within 30 days of the device being supplied in Australia.
  2. Direct Marking: This milestone applies specifically to reusable devices that are reprocessed between uses on different patients. Manufacturers must permanently mark the UDI on the device itself, and sponsors must update the AusUDID record accordingly.

Compliance Deadline: Manufacturers and sponsors should be aware of the upcoming mandatory compliance dates. Class III and Class IIb medical devices are the first groups required to meet the UDI labelling and record submission milestone starting 1 July 2026.

While other device classes have later deadlines, such as Class IIa (1 July 2027) and Class Is and high-risk IVDs (1 July 2028), the TGA encourages all manufacturers to begin preparations early. Early preparation is especially vital for those managing large volumes of devices or those needing to establish new internal data management processes.

What does this mean for the medical device industry? 

Manufacturers and sponsors should immediately review their product portfolios against the new TGA guidance to determine their specific compliance dates and whether they qualify for any transitional arrangements. Failure to comply with these Essential Principles can result in regulatory action, including the suspension or cancellation of devices from the Australian Register of Therapeutic Goods (ARTG).

Do you need support assessing your products for the Australian market? Contact us, we are happy to help!